Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Biosynthesis of PGD2 in Vivo

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-01-12
Last Posted Date
2021-06-23
Lead Sponsor
University of Pennsylvania
Target Recruit Count
9
Registration Number
NCT01275300
Locations
🇺🇸

University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass

First Posted Date
2010-12-31
Last Posted Date
2010-12-31
Lead Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Target Recruit Count
200
Registration Number
NCT01268917
Locations
🇨🇳

Fuwai Hospital, Beijing, China

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

First Posted Date
2010-12-14
Last Posted Date
2017-01-11
Lead Sponsor
Ronald Hoffman
Target Recruit Count
135
Registration Number
NCT01259817
Locations
🇺🇸

The Palo Alto Clinic, Palo Alto, California, United States

🇺🇸

Georgetown University Medical Center, Washington, District of Columbia, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 18 locations

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

First Posted Date
2010-12-14
Last Posted Date
2019-04-30
Lead Sponsor
Ronald Hoffman
Target Recruit Count
168
Registration Number
NCT01259856
Locations
🇺🇸

Mayo Clinic, Scottsdale, Arizona, United States

🇮🇹

University Of Florence, Florence, Italy

🇺🇸

Stanford University School of Medicine, Stanford, California, United States

and more 22 locations

Type 2 Diabetes Mellitus and Atherosclerosis

First Posted Date
2010-11-30
Last Posted Date
2012-11-28
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
80
Registration Number
NCT01250340
Locations
🇮🇹

Sapienza Università di Roma, Rome, Italy

Aspirin Mouthwash in Treating Patients With Oral Leukoplakia

Phase 1
Completed
Conditions
First Posted Date
2010-11-10
Last Posted Date
2013-08-12
Lead Sponsor
Institute of Head and Neck Studies and Education, United Kingdom
Target Recruit Count
40
Registration Number
NCT01238185
Locations
🇬🇧

Institute of Head and Neck Studies and Education, Coventry, England, United Kingdom

🇬🇧

University of Birmingham, Birmingham, England, United Kingdom

Distal Venous Arterialisation of Ischemic Limb

First Posted Date
2010-09-30
Last Posted Date
2010-09-30
Lead Sponsor
Clinical Centre of Serbia
Target Recruit Count
30
Registration Number
NCT01211925
Locations
🇷🇸

Clinical Center of Serbia, Belgrade, Serbia

Aspirin Dosing in Diabetic Patients

First Posted Date
2010-09-15
Last Posted Date
2012-03-06
Lead Sponsor
University of Florida
Target Recruit Count
20
Registration Number
NCT01201785
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

Study to Evaluate the Interaction Between Aspirin and Nexium

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-09-10
Last Posted Date
2010-11-19
Lead Sponsor
AstraZeneca
Target Recruit Count
34
Registration Number
NCT01199328
Locations
🇺🇸

Research Site, Springfield, Missouri, United States

Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients

Phase 4
Withdrawn
Conditions
Interventions
First Posted Date
2010-09-10
Last Posted Date
2019-01-17
Lead Sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Registration Number
NCT01198379
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath